Jonathan Siegal Sells 1,092 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL - Get Free Report) insider Jonathan Siegal sold 1,092 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the sale, the insider now directly owns 1,206 shares in the company, valued at $74,759.94. This represents a 47.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jonathan Siegal also recently made the following trade(s):

• On Tuesday, January 28th, Jonathan Siegal sold 3,908 shares of Vericel stock. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92.

Vericel Price Performance

VCEL traded down $1.14 during mid-day trading on Tuesday, hitting $57.51. The stock had a trading volume of 207,123 shares, compared to its average volume of 403,842. The stock's fifty day simple moving average is $57.84 and its 200-day simple moving average is $51.19. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of 958.66 and a beta of 1.72. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00.

Institutional Investors Weigh In On Vericel

Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Vericel by 214.0% during the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock worth $24,837,000 after acquiring an additional 400,667 shares in the last quarter. Stifel Financial Corp increased its position in shares of Vericel by 40.0% during the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock worth $1,186,000 after acquiring an additional 8,020 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock worth $48,768,000 after acquiring an additional 9,613 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Vericel during the third quarter worth $563,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Vericel by 4.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company's stock worth $45,590,000 after acquiring an additional 47,108 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on VCEL. Canaccord Genuity Group increased their price target on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Stephens reissued an "overweight" rating and set a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial increased their price target on shares of Vericel from $61.00 to $67.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. BTIG Research increased their price target on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Vericel in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $63.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.